Journal of the American Academy of Dermatology 2025 Aug 29
Ultralow-dose rituximab in pemphigus: Weighing clinical benefits against immunologic limitations.
Related Questions
Do you feel these are clinically meaningful?
New answer by at University of Pennsylvania (January 26, 2026)
I don’t think there is a documented big difference in safety to use low-dose rituximab. It is more likely that the pathogenic B cells will come back quicker with low-dose ri...